©The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Aug 15, 2017; 9(8): 333-340
Published online Aug 15, 2017. doi: 10.4251/wjgo.v9.i8.333
Published online Aug 15, 2017. doi: 10.4251/wjgo.v9.i8.333
Impact of tumour histological subtype on chemotherapy outcome in advanced oesophageal cancer
Michael Davidson, Ian Chau, David Cunningham, Komel Khabra, Naureen Starling, Royal Marsden Hospital NHS Foundation Trust, London and Surrey, London SM25PT, United Kingdom
Timothy Iveson, Southampton University Hospital NHS Trust and Salisbury Hospital NHS Foundation Trust, Southampton SO16 6YD, United Kingdom
Tamas Hickish, Department of Haematology and Oncology, Bournemouth University and Poole Hospital NHS Trust, Dorset BH15 2JB, United Kingdom
Matthew Seymour, St James’s Institute of Oncology, St James’s Hospital, Leeds LS9 7TF, United Kingdom
Author contributions: Davidson M prepared manuscript; Khabra K performed statistical analysis; Chau I, Cunningham D, Iveson T, Hickish T, Seymour M and Starling N critically reviewed manuscript.
Institutional review board statement: All three studies included in the following analysis were reviewed by approved research and ethics committees in accordance with UK Medical Research Council regulations and results have previously been published in peer-reviewed journals.
Informed consent statement: All study participants in the three studies included in the following analysis provided informed written consent prior to study enrollment.
Conflict-of-interest statement: The authors declare no conflicts of interest.
Data sharing statement: No additional data are available.
Correspondence to: Dr. Naureen Starling, Royal Marsden Hospital NHS Foundation Trust, London and Surrey, Fulham Road, London SM25PT, United Kingdom. naureen.starling@rmh.nhs.uk
Fax: +44-208-6439414
Received: January 31, 2017
Peer-review started: February 7, 2017
First decision: March 28, 2017
Revised: May 10, 2017
Accepted: May 18, 2017
Article in press: May 19, 2017
Published online: August 15, 2017
Processing time: 191 Days and 1.6 Hours
Peer-review started: February 7, 2017
First decision: March 28, 2017
Revised: May 10, 2017
Accepted: May 18, 2017
Article in press: May 19, 2017
Published online: August 15, 2017
Processing time: 191 Days and 1.6 Hours
Core Tip
Core tip: There is a lack of published data on differential treatment response according to histology in oesophageal cancer. This paper shows improved response rates with first-line chemotherapy and a trend towards improved survival in adenocarcinoma compared to squamous cell carcinoma (SCC). It is increasingly recognised that these histological subtypes represent discrete disease entities with divergent treatment pathways in both the early stage and advanced settings. Novel treatments in SCC remain sparse and there are few dedicated trials in this subtype. This data highlights the poor outcomes seen with chemotherapy alone and the need for further research, particularly for SCC.